hVIVO plc Statement regarding share price (3474K)
10 April 2018 - 4:01PM
UK Regulatory
TIDMHVO
RNS Number : 3474K
hVIVO plc
10 April 2018
For immediate release 7.00am: 10 April 2018
HVIVO PLC
("hVIVO" or the "Company")
Statement regarding share price
The Board of hVIVO plc (AIM: HVO) notes the sudden and extreme
fall in its share price in recent days and confirms that it knows
of no reason for such a fall.
The Company announced initial results on 26 March 2018 of a
Phase IIb study examining FLU-v as a potential universal vaccine
against influenza (flu) which, although only indicating a trend to
statistical significance of the primary endpoint, did demonstrate a
statistically significant reduction in overt flu symptoms and gives
the Board cause for optimism that its investment in FLU-v (through
its joint venture Imutex Limited) has potentially significant
future value.
The Company will announce its audited preliminary results for
the year ended 31 December 2017 on 19 April 2018. Financial results
for the year ended 31 December 2017 are expected to be in-line with
market expectations, with cash as at 31 December 2017 of GBP20.3
million (2016: GBP25.7 million) which is markedly ahead of
expectations.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive
Officer)
Graham Yeatman (Chief Financial
& Business Officer)
Media Enquiries +1 919 710 9658
Susan Flood
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke
(Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster
Mitchell (UK) +44 203 727 1000
Notes to Editors:
About hVIVO plc
hVIVO plc ("hVIVO") is developing a pioneering human-based
analytical platform to accelerate drug discovery and development in
airways diseases. Leveraging human disease models in flu, RSV and
asthma exacerbation, the hVIVO platform captures disease in motion,
illuminating the entire disease life cycle from healthy to sick and
back to health. Based in the UK, market leader hVIVO has conducted
more than 50 clinical studies, inoculated over 2500 volunteers and
has three first-in-class therapies currently in development with a
growing pre-clinical pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
SPMILMBTMBJMTLP
(END) Dow Jones Newswires
April 10, 2018 02:01 ET (06:01 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024